Search

Your search keyword '"Lazaro, Conxi"' showing total 550 results

Search Constraints

Start Over You searched for: Author "Lazaro, Conxi" Remove constraint Author: "Lazaro, Conxi"
550 results on '"Lazaro, Conxi"'

Search Results

1. CTNND1 is involved in germline predisposition to early-onset gastric cancer by affecting cell-to-cell interactions

2. Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2

3. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

5. Cancer genetic counseling in Chile: Addressing barriers, confronting challenges, and seizing opportunities in an underserved Latin American Community

6. A New Set of in Silico Tools to Support the Interpretation of ATM Missense Variants Using Graphical Analysis

7. Haplotype analysis of the internationally distributed BRCA1 c.3331_3334delCAAG founder mutation reveals a common ancestral origin in Iberia

8. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

9. Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors

10. Deep genomic analysis of malignant peripheral nerve sheath tumor cell lines challenges current malignant peripheral nerve sheath tumor diagnosis

11. ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1

12. Genotype-first approach to identify associations between CDH1 germline variants and cancer phenotypes: a multicentre study by the European Reference Network on Genetic Tumour Risk Syndromes

13. Population based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high grade serous ovarian cancer

14. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

16. Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3.

18. Immune Cell Associations with Cancer Risk

19. Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women.

20. RANKL/RANK control Brca1 mutation-driven mammary tumors

21. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.

22. AhR controls redox homeostasis and shapes the tumor microenvironment in BRCA1-associated breast cancer

24. The third international meeting on genetic disorders in the RAS/MAPK pathway: Towards a therapeutic approach

25. Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer

26. Identification of six new susceptibility loci for invasive epithelial ovarian cancer.

28. Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk

30. Supplementary Table 2 from Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

31. Supplementary Tables S1-S9 from Mutational Heterogeneity in APC and KRAS Arises at the Crypt Level and Leads to Polyclonality in Early Colorectal Tumorigenesis

32. Supplementary Figures S1-S15 from Mutational Heterogeneity in APC and KRAS Arises at the Crypt Level and Leads to Polyclonality in Early Colorectal Tumorigenesis

33. Supplementary Tables 1-4 from Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

34. Supplementary Table 3 from Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

35. Data from Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

36. Supplementary Tables 1-9 from Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)

37. Data from Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction

38. Supplementary Methods, Tables 1-3, Figure 1 from Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction

40. Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2.

41. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer

42. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

43. ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1

44. Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2

45. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

47. Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants

48. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores

50. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores

Catalog

Books, media, physical & digital resources